Book Now
Fuzeon
Of the total drug interactions, 3 are major, 1 is moderate, and 3 are minor
It is a synthetic peptide which binds to the HIV glycoprotein 41 (gp41), blocking fusion of the viral and cellular membranes
Optimized Regimen Only Study 1 (TORO 1) was a randomized, open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency virus type 1 (HIV-1) fusion inhibitor
enfuvirtide and zidovudine both increase risk of immune reconstitution syndrome
Known hypersensitivity to enfuvirtide or any ingredient in the formulation
Enfuvirtide must be given SQ; severity of reactions increases if given intramuscularly
Enfuvirtide (also known as T-20) is a linear 36-amino-acid peptide (molecular mass 4,492 Da) that is produced synthetically in a process involving more than 100 steps to give a powder for Enfuvirtide may cause side effects
enfuvirtide and lamivudine both increase risk of immune reconstitution syndrome
Кафедра Enfuvirtide (also known as Fuzeon, T-20, or DP-178) is a well-described antiviral fusion inhibitor which prevents human immunodeficiency virus type 1 (HIV-1) from entering host cells (28, 38, 57)
Enfuvirtide is a good therapeutic option as rescue therapy in combination with other active antiretrovirals and works against different HIV-1 variants, including all group M subtypes and group O